Dong-E-E-Jiao Co Ltd
SZSE:000423
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dong-E-E-Jiao Co Ltd
Cash from Operating Activities
Dong-E-E-Jiao Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Dong-E-E-Jiao Co Ltd
SZSE:000423
|
Cash from Operating Activities
¥2.6B
|
CAGR 3-Years
3%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cash from Operating Activities
¥4.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cash from Operating Activities
¥11.5B
|
CAGR 3-Years
105%
|
CAGR 5-Years
41%
|
CAGR 10-Years
17%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cash from Operating Activities
¥4.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cash from Operating Activities
¥8.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
23%
|
CAGR 10-Years
25%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cash from Operating Activities
¥4.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
171%
|
CAGR 10-Years
N/A
|
|
Dong-E-E-Jiao Co Ltd
Glance View
In the heart of China's Shandong Province lies Dong-E-E-Jiao Co Ltd, a company deeply rooted in the traditions of Chinese medicinal culture yet driven by the dynamics of a modern corporation. Established in the early 1950s, Dong-E-E-Jiao takes its name from its primary product, "ejiao," a traditional medicine derived from donkey-hide gelatin. Traditionally used in Chinese medicine for its purported benefits in nourishing blood and enhancing vitality, ejiao forms the cornerstone of Dong-E-E-Jiao's product line. At the company’s state-of-the-art facilities, these gelatin products are manufactured with a blend of time-tested practices and contemporary techniques, ensuring quality and efficacy that cater to both domestic and international markets. Dong-E-E-Jiao’s approach to business revolves around harnessing the age-old wisdom of Chinese medicine, coupled with a solid understanding of global health and wellness trends. Beyond gelatin products, the company has diversified into related segments, offering nutritional supplements, beauty products, and contemporary health foods—all linked by their heritage in traditional Chinese medicine. This diversification strategy has opened multiple revenue streams, allowing Dong-E-E-Jiao to expand its market reach while anchoring its brand in authenticity and trust. Sales are driven through a mix of direct retail channels, partnerships with pharmacies, and an increasing online presence, ensuring that their products remain accessible to a broad array of consumers. In this way, Dong-E-E-Jiao balances the dual imperatives of tradition and innovation to drive its business forward.
See Also
What is Dong-E-E-Jiao Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
2.6B
CNY
Based on the financial report for Mar 31, 2026, Dong-E-E-Jiao Co Ltd's Cash from Operating Activities amounts to 2.6B CNY.
What is Dong-E-E-Jiao Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
17%
Over the last year, the Cash from Operating Activities growth was 113%. The average annual Cash from Operating Activities growth rates for Dong-E-E-Jiao Co Ltd have been 3% over the past three years , 9% over the past five years , and 17% over the past ten years .